LEXARIA BIOSCIENCE CORP. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.37 USD | +0.85% |
|
+4.64% | +89.60% |
| Apr. 16 | Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study | MT |
| Apr. 16 | Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study | CI |
Valuation
| Fiscal Period: August | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 54.26 | 31.14 | 35.36 | 17.61 | 8.495 | 30.28 | - | - |
| Enterprise Value (EV) 1 | 54.26 | 31.14 | 35.36 | 17.61 | 8.495 | 30.28 | 30.28 | 30.28 |
| P/E ratio | - | -6.92 x | - | -2.39 x | -1.04 x | -4.39 x | -4.75 x | -3.92 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 244 x | - | 48.9 x | 69 x | 37.6 x | 62.9 x | 62.1 x | - |
| EV / Revenue | 244 x | - | 48.9 x | 69 x | 37.6 x | 62.9 x | 62.1 x | - |
| EV / EBITDA | -14,296,341 x | - | -6,342,044 x | - | - | - | - | - |
| EV / FCF | -14,858,565 x | - | -8,689,172 x | - | -1,436,253 x | - | - | - |
| FCF Yield | -0% | - | -0% | - | -0% | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 2,621 | 3,001 | 5,685 | 5,951 | 8,092 | 12,886 | - | - |
| Reference price 2 | 20.70 | 10.38 | 6.220 | 2.960 | 1.050 | 2.350 | 2.350 | 2.350 |
| Announcement Date | 11/14/19 | 10/14/20 | 11/29/21 | 11/28/22 | 11/20/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: August | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.2226 | - | 0.7227 | 0.2554 | 0.2262 | 0.4815 | 0.4875 | - |
| EBITDA | -3.795 | - | -5.575 | - | - | - | - | - |
| EBIT 1 | - | - | - | -7.384 | -6.534 | -6.254 | -7.398 | -11.76 |
| Operating Margin | - | - | - | -2,891.01% | -2,888.48% | -1,298.86% | -1,517.54% | - |
| Earnings before Tax (EBT) 1 | - | - | - | -7.384 | -6.713 | -6.277 | -7.398 | -11.76 |
| Net income 1 | - | -3.934 | - | -7.384 | -6.665 | -6.277 | -7.398 | -11.76 |
| Net margin | - | - | - | -2,891.01% | -2,946.33% | -1,303.63% | -1,517.54% | - |
| EPS 2 | - | -1.500 | - | -1.240 | -1.010 | -0.5350 | -0.4950 | -0.6000 |
| Free Cash Flow | -3.652 | - | -4.069 | - | -5.915 | - | - | - |
| FCF margin | -1,640.42% | - | -563.02% | - | -2,614.82% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/14/19 | 10/14/20 | 11/29/21 | 11/28/22 | 11/20/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: August | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.0306 | 0.0997 | 0.1112 | - | 0.0932 | -0.00343 | 0.1513 | 0.145 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -1.449 | -2.418 | -1.513 | - | -2.384 | -1.071 | -1.139 | -0.668 | -1.907 | -1.969 |
| Operating Margin | -4,726.49% | -2,425.13% | -1,361.37% | - | -2,558.85% | 31,210.2% | -753% | -460.7% | - | - |
| Earnings before Tax (EBT) 1 | -1.449 | -2.418 | -1.513 | - | -2.384 | -1.249 | -1.185 | -0.6527 | -1.907 | -1.969 |
| Net income 1 | -1.426 | -2.383 | -1.513 | -1.298 | -2.372 | -1.239 | -1.179 | -0.6495 | -1.907 | -1.969 |
| Net margin | -4,651.81% | -2,389.62% | -1,361.37% | - | -2,545.9% | 36,131.78% | -779.56% | -447.96% | - | - |
| EPS 2 | -0.2500 | -0.4100 | -0.2400 | -0.2200 | -0.3700 | -0.1200 | -0.1300 | -0.0600 | -0.1300 | -0.1200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 4/11/22 | 7/14/22 | 11/28/22 | 4/14/23 | 7/14/23 | 11/20/23 | 1/12/24 | 4/9/24 | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: August | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -3.65 | - | -4.07 | - | -5.91 | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | 0.03 | - | - | - |
| Capex / Sales | - | - | - | - | 14.92% | - | - | - |
| Announcement Date | 11/14/19 | 10/14/20 | 11/29/21 | 11/28/22 | 11/20/23 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.35
USD
Average target price
11
USD
Spread / Average Target
+368.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +89.60% | 30.28M | |
| +25.52% | 661B | |
| +26.74% | 566B | |
| -6.59% | 352B | |
| +20.23% | 332B | |
| +2.95% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -5.20% | 145B |
- Stock Market
- Equities
- LEXX Stock
- Financials Lexaria Bioscience Corp.
